The Clinical and Cost Effectiveness of Vortioxetine for the Treatment of a Major Depressive Episode in Patients With Failed Prior Antidepressant Therapy: A Critique of the Evidence-Reference-Cited by-同舟云学术

The Clinical and Cost Effectiveness of Vortioxetine for the Treatment of a Major Depressive Episode in Patients With Failed Prior Antidepressant Therapy: A Critique of the Evidence

Published:2016-06-11 Issue:9 Volume:34 Page:901-912
ISSN:1170-7690
Container-title:PharmacoEconomics
language:en
Short-container-title:PharmacoEconomics

Author:

Lomas James,Llewellyn Alexis,Soares Marta,Simmonds Mark,Wright Kath,Eastwood Alison,Palmer Stephen

Funder

National Institute for Health Research

Publisher

Springer Science and Business Media LLC

Subject

Public Health, Environmental and Occupational Health,Health Policy,Pharmacology

Link

http://link.springer.com/content/pdf/10.1007/s40273-016-0417-9.pdf

Reference15 articles.

1. NICE. Guide to the single technology appraisal process. 2009. Available at: https://www.nice.org.uk/Media/Default/About/what-we-do/NICE-guidance/NICE-technology-appraisals/Guide-to-the-single-technology-appraisal-process.pdf . Accessed 2 June 2016.

2. Simmonds M, Lomas J, Llewellyn A, Soares M, Wright K, Eastwood A, et al. Vortioxetine for treating major depressive disorder: a single technology appraisal. CRD/CHE Technology Assessment Group; 2015.

3. NICE. Vortioxetine for treating major depressive episodes. 2015. Available at: https://www.nice.org.uk/guidance/ta367 .

4. NICE. Depression in adults: recognition and management. 2009. Available at: https://www.nice.org.uk/Guidance/CG90 . Accessed 2 June 2016.

5. Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997;50(6):683–91.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Incidence and Costs of Adverse Events Associated with Antidepressants: Results from a Systematic Review, Network Meta-Analysis and Multi-Country Economic Model;Neuropsychiatric Disease and Treatment;2022-06

2. Extended Producer Responsibility for Pharmaceuticals;Manufacturing & Service Operations Management;2022-01

3. Key considerations in the pharmacological management of treatment-resistant depression;Expert Opinion on Pharmacotherapy;2021-07-21

4. Vortioxetine: Clinical Pharmacokinetics and Drug Interactions;Clinical Pharmacokinetics;2017-11-30

5. Cost-utility evaluation of vortioxetine in patients with Major Depressive Disorder experiencing inadequate response to alternative antidepressants in the United Kingdom;Journal of Affective Disorders;2017-08